Naresh M Punjabi1, Brock A Beamer. 1. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. npunjabi@jhmi.edu
Abstract
RATIONALE: It is well established that sleep-disordered breathing (SDB) is independently associated with insulin resistance, glucose intolerance, and type 2 diabetes mellitus. However, data on whether SDB alters in vivo kinetics of glucose and insulin are lacking. OBJECTIVES: The primary goal of this study was to use the frequently sampled intravenous glucose tolerance test (FSIVGTT) in subjects with and without SDB to model the in vivo kinetics of glucose and insulin. Minimal model analysis of the FSIVGTT data was used to derive parameters of insulin sensitivity, glucose effectiveness (a measure of the ability of glucose to mediate its own disposal), and pancreatic beta-cell function. RESULTS: A total of 118 nondiabetic subjects underwent polysomnography, the FSIVGTT, and body composition measurements including determination of percent body fat. Compared with normal subjects (apnea-hypopnea index < 5 events/h), those with mild, moderate, and severe SDB displayed a 26.7, 36.5 and 43.7% reduction in insulin sensitivity, respectively, independent of age, sex, race, and percent body fat. The disposition index, an integrated measure of pancreatic beta-cell function, was also reduced in patients with moderate to severe SDB. The decrease in insulin sensitivity and the disposition index were correlated with the average degree of oxyhemoglobin desaturation. In contrast, glucose effectiveness was negatively correlated with the frequency of respiratory event-related arousals. CONCLUSIONS: The results of this study suggest that, independent of adiposity, SDB is associated with impairments in insulin sensitivity, glucose effectiveness, and pancreatic beta-cell function. Collectively, these defects may increase the risk of glucose intolerance and type 2 diabetes mellitus in SDB.
RATIONALE: It is well established that sleep-disordered breathing (SDB) is independently associated with insulin resistance, glucose intolerance, and type 2 diabetes mellitus. However, data on whether SDB alters in vivo kinetics of glucose and insulin are lacking. OBJECTIVES: The primary goal of this study was to use the frequently sampled intravenous glucose tolerance test (FSIVGTT) in subjects with and without SDB to model the in vivo kinetics of glucose and insulin. Minimal model analysis of the FSIVGTT data was used to derive parameters of insulin sensitivity, glucose effectiveness (a measure of the ability of glucose to mediate its own disposal), and pancreatic beta-cell function. RESULTS: A total of 118 nondiabetic subjects underwent polysomnography, the FSIVGTT, and body composition measurements including determination of percent body fat. Compared with normal subjects (apnea-hypopnea index < 5 events/h), those with mild, moderate, and severe SDB displayed a 26.7, 36.5 and 43.7% reduction in insulin sensitivity, respectively, independent of age, sex, race, and percent body fat. The disposition index, an integrated measure of pancreatic beta-cell function, was also reduced in patients with moderate to severe SDB. The decrease in insulin sensitivity and the disposition index were correlated with the average degree of oxyhemoglobin desaturation. In contrast, glucose effectiveness was negatively correlated with the frequency of respiratory event-related arousals. CONCLUSIONS: The results of this study suggest that, independent of adiposity, SDB is associated with impairments in insulin sensitivity, glucose effectiveness, and pancreatic beta-cell function. Collectively, these defects may increase the risk of glucose intolerance and type 2 diabetes mellitus in SDB.
Authors: T Hori; Y Sugita; E Koga; S Shirakawa; K Inoue; S Uchida; H Kuwahara; M Kousaka; T Kobayashi; Y Tsuji; M Terashima; K Fukuda; N Fukuda Journal: Psychiatry Clin Neurosci Date: 2001-06 Impact factor: 5.188
Authors: Naresh M Punjabi; Murtuza M Ahmed; Vsevolod Y Polotsky; Brock A Beamer; Christopher P O'Donnell Journal: Respir Physiol Neurobiol Date: 2003-07-16 Impact factor: 1.931
Authors: Nathaniel S Marshall; Keith K H Wong; Peter Y Liu; Stewart R J Cullen; Matthew W Knuiman; Ronald R Grunstein Journal: Sleep Date: 2008-08 Impact factor: 5.849
Authors: A S Jackson; P R Stanforth; J Gagnon; T Rankinen; A S Leon; D C Rao; J S Skinner; C Bouchard; J H Wilmore Journal: Int J Obes Relat Metab Disord Date: 2002-06
Authors: Ray C Boston; Darko Stefanovski; Peter J Moate; Anne E Sumner; Richard M Watanabe; Richard N Bergman Journal: Diabetes Technol Ther Date: 2003 Impact factor: 6.118
Authors: Daniel J Lesser; Rajeev Bhatia; Winston H Tran; Flavia Oliveira; Ricardo Ortega; Thomas G Keens; Steven D Mittelman; Michael C K Khoo; Sally L Davidson Ward Journal: Pediatr Res Date: 2012-06-05 Impact factor: 3.756
Authors: Antonella Zanobetti; Susan Redline; Joel Schwartz; Dennis Rosen; Sanjay Patel; George T O'Connor; Michael Lebowitz; Brent A Coull; Diane R Gold Journal: Am J Respir Crit Care Med Date: 2010-05-27 Impact factor: 21.405
Authors: Luciano F Drager; Vsevolod Y Polotsky; Christopher P O'Donnell; Sergio L Cravo; Geraldo Lorenzi-Filho; Benedito H Machado Journal: Am J Physiol Heart Circ Physiol Date: 2015-07-31 Impact factor: 4.733
Authors: Ali Azarbarzin; Scott A Sands; Luigi Taranto-Montemurro; Daniel Vena; Tamar Sofer; Sang-Wook Kim; Katie L Stone; David P White; Andrew Wellman; Susan Redline Journal: Chest Date: 2020-04-13 Impact factor: 9.410